Advent Capital Management’s Insmed INSM Stock Holding History

Advent Capital Management’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-50	Closed	-$1K	–	302
2018 Q1	$1K	Buy	+50	New	+$1.32K	﹤0.01%	271

Other funds holding INSM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Advent Capital Management's INSM Position: Q2 2018 in Review

Advent Capital Management sold out of Insmed (INSM) in Q2 2018, closing a stake of 50 shares — an estimated $1K sold.

Advent Capital Management first reported a position in INSM in Q1 2018 and held it in 1 quarter. The position peaked at $1K in Q1 2018. 127 funds tracked by Wall St. Rank hold INSM as of Q2 2018.

Advent Capital Management reported no remaining Insmed position as of Q2 2018 after selling out during the quarter.
Advent Capital Management sold 50 Insmed shares in Q2 2018, an estimated $1K.
Advent Capital Management first reported a position in Insmed in Q1 2018 and held it in 1 quarter.
Advent Capital Management's Insmed position peaked at $1K in Q1 2018.
127 funds tracked by Wall St. Rank held Insmed as of Q2 2018.

Based on Advent Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.